4//SEC Filing
Weisman Harlan F 4
Accession 0001213900-24-035077
CIK 0001733413other
Filed
Apr 21, 8:00 PM ET
Accepted
Apr 22, 8:47 PM ET
Size
6.4 KB
Accession
0001213900-24-035077
Insider Transaction Report
Form 4
Weisman Harlan F
Director
Transactions
- Award
Restricted stock units
2024-04-18+44,967→ 44,967 total→ Common stock (44,967 underlying)
Footnotes (2)
- [F1]Each restricted stock unit, or RSU, represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted to the Reporting Person, in part, in consideration of their agreement to defer 50% of their cash compensation until such time as the Issuer has completed its next equity financing.
- [F2]The settlement of the RSUs is contingent on stockholder approval, at the Issuer's 2024 annual meeting of stockholders, or Annual Meeting, of an amendment to increase the share reserve under the Issuer's 2021 Stock Incentive Plan, or 2021 Plan. The RSUs shall terminate if the Issuer's stockholders do not approve the proposed amendment to the 2021 Plan at the Annual Meeting. Subject to stockholder approval of the amendment to the 2021 Plan, and subject further to the consummation of the Issuer's next equity financing, the RSUs will settle in four equal installments, with the first installment settling on completion of the Issuer's next equity financing and the other three installments settling on the 15th, 30th and 45th day following the completion of the next equity financing.
Documents
Issuer
TFF Pharmaceuticals, Inc.
CIK 0001733413
Entity typeother
Related Parties
1- filerCIK 0001555563
Filing Metadata
- Form type
- 4
- Filed
- Apr 21, 8:00 PM ET
- Accepted
- Apr 22, 8:47 PM ET
- Size
- 6.4 KB